News

The Motley Fool: Merck’s risks and potential
There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...
Merck's potential blockbuster cholesterol pill succeeds in late-stage studies
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...
Merck Wins US Approval for Shot to Prevent Infant RSV
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
Fierce Biotech7d
Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...
Explore more
STAT7d
Merck’s RSV preventive antibody for infants is approved by FDA
The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.
BioPharma Dive7d
Merck antibody drug for RSV approved by FDA
Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...
Merck Manuals Launches AI-powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources
Merck Manuals, a comprehensive digital health resource, announced today it has launched a new search tool enhanced by artificial intelligence to provide patients and other health care consumers with ...